Overview

Quercetin in Children With Fanconi Anemia; a Pilot Study

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure (BMF), congenital abnormalities and a predisposition to malignancy.

Phase:

Phase 1

Details

Lead Sponsor:

Children's Hospital Medical Center, Cincinnati

Collaborator:

Food and Drug Administration (FDA)

Treatments:

Quercetin